Seton Products Ltd - search results

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

hydrocortisone iodoquinol- hydrocortisone, iodoquinol cream

seton pharmaceuticals - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj), iodoquinol (unii: 63w7ie88k8) (iodoquinol - unii:63w7ie88k8) - based on a review of a related drug by the national research council and subsequent fda classification for that drug, the indications are as follows: "possibly" effective: contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo. final classification of the less-than-effective indications requires further investigation. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

methenamine mandelate tablet, film coated

seton pharmaceuticals - methenamine mandelate (unii: 695n30cinr) (methenamine - unii:j50oix95qv) - methenamine mandelate is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also those neurologic diseases leading to an infected residual urine. when used as recommended, methenamine mandelate is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. pathogens resistant to other antibacterial agents may respond to methenamine mandelate because of the nonspecific effect of formaldehyde formed in an acid urine. prophylactic use rationale: urine is a good culture medium for many urinary pathogens. inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. there is a growing body of evidence that lon

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

memantine hydrochloride- memantine hydrochloride oral solution

seton pharmaceuticals - memantine hydrochloride (unii: jy0wd0ua60) (memantine - unii:w8o17sjf3t) - memantine hydrochloride is indicated for the treatment of moderate to severe dementia of the alzheimer’s type. memantine hydrochloride is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. pregnancy category b there are no adequate and well-controlled studies of memantine in pregnant women. memantine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. memantine given orally to pregnant rats and pregnant rabbits during the period of organogenesis was not teratogenic up to the highest doses tested (18 mg/kg/day in rats and 30 mg/kg/day in rabbits, which are 9 and 30 times, respectively, the maximum recommended human dose [mrhd] on a mg/m2 basis). slight maternal toxicity, decreased pup weights and an increased incidence of non-ossified cervical vertebrae were seen at an oral dose of 18 mg/kg/day in a study in which rats were given oral memantine beginning pre-mating and continuing through the postpartum period. slight maternal toxicity and decreased pup weights were also seen at this dose in a study in which rats were treated from day 15 of gestation through the postpartum period. the no-effect dose for these effects was 6 mg/kg, which is 3 times the mrhd on a mg/m2 basis. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when memantine hydrochloride is administered to a nursing mother. safety and effectiveness in pediatric patients have not been established. the majority of people with alzheimer’s disease are 65 years and older. in the clinical studies of memantine hydrochloride the mean age of patients was approximately 76; over 90% of patients were 65 years and older, 60% were 75 years and older, and 12% were at or above 85 years of age. the efficacy and safety data presented in the clinical trial sections were obtained from these patients. there were no clinically meaningful differences in most adverse events reported by patient groups ≥65 years old and <65 year old. no dosage adjustment is needed in patients with mild or moderate renal impairment. a dosage reduction is recommended in patients with severe renal impairment [see dosage and administration (2) and clinical pharmacology (12.3)] . no dosage adjustment is needed in patients with mild or moderate hepatic impairment. memantine hydrochloride should be administered with caution to patients with severe hepatic impairment [see dosage and administration (2) and clinical pharmacology (12.3)] . instructions for use memantine hydrochloride (me-man-teen hye-droe-klor-ide) oral solution directions for using your memantine hydrochloride oral solution read these instructions before taking memantine hydrochloride oral solution and each time you get a refill. there may be new information. this information does not take the place of talking to your doctor about your medical condition or your treatment. preparing your dose of memantine hydrochloride oral solution. you will need the following supplies: - memantine hydrochloride oral solution bottle with child-resistant cap - press-in bottle adaptor - oral dosing syringe - prescribing information instructions this patient information and instructions for use have been approved by the u.s. food and drug administration. manufactured for: seton pharmaceuticals, wall, nj 07719 1 (800) 510-3401 manufactured by: medley pharmaceuticals ltd. plot no. 18 & 19, zari causeway road kachigram, daman 396210, india revised 02/2021